Bosh sahifa0460 • HKG
add
Sihuan Pharmaceutical Holdings Group Ltd
Yopilish kursi
0,59 $
Kunlik diapazon
0,57 $ - 0,59 $
Yillik diapazon
0,49 $ - 1,02 $
Bozor kapitalizatsiyasi
5,40 mlrd HKD
Oʻrtacha hajm
12,69 mln
Narx/foyda
-
Dividend daromadliligi
3,62%
Asosiy maydon
HKG
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(CNY) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 474,85 mln | -10,04% |
Joriy xarajat | 301,93 mln | -12,13% |
Sof foyda | -16,71 mln | 32,67% |
Sof foyda marjasi | -3,52 | 25,11% |
Har bir ulushga tushum | — | — |
EBITDA | 56,91 mln | -32,62% |
Amaldagi soliq stavkasi | -253,73% | — |
Balans
Jami aktivlari
Jami passivlari
(CNY) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 4,86 mlrd | 7,86% |
Jami aktivlari | 11,53 mlrd | -2,11% |
Jami passivlari | 6,44 mlrd | -1,32% |
Umumiy kapital | 5,09 mlrd | — |
Tarqatilgan aksiyalar | 9,32 mlrd | — |
Narxi/balansdagi bahosi | 1,26 | — |
Aktivlardan daromad | 0,05% | — |
Kapitaldan daromad | 0,09% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(CNY) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -16,71 mln | 32,67% |
Operatsiyalardan naqd pul | 18,23 mln | 28,75% |
Sarmoyadan naqd pul | 126,63 mln | 152,35% |
Moliyadan naqd pul | -29,16 mln | 73,91% |
Naqd pulning sof oʻzgarishi | 115,70 mln | 344,01% |
Boʻsh pul | -12,85 mln | -53,24% |
Haqida
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province. The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.
Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease. The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan. Wikipedia
CEO
Tashkil etilgan
2001
Sayt
Xodimlar soni
2 648